Stocks Health care BLTE
NASDAQ · Health careBelite Bio, Inc (BLTE)
It posted a net loss of $77.6M. In fiscal 2025 capital spending exceeded operating cash flow by $37.1M. At December 31, 2025 it held $352.9M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 31, 2026.
What Belite Bio, Inc does
Belite Bio, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BLTE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$77.6M | -$2.31 | -$37.1M |
| 2024 | n/a | -$36.1M | -$1.18 | -$29.4M |
| 2023 | n/a | -$31.6M | -$1.19 | -$29.9M |
| 2022 | n/a | -$12.6M | -$0.63 | -$11.9M |
| 2022 | n/a | -$9.7M | -$1.01 | -$7.5M |
| 2020 | n/a | -$5.8M | -$0.65 | n/a |
Latest SEC filings
What Belite Bio, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- August 13, 2026
- August 11, 2026
- June 15, 2026
- May 20, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- April 21, 2026
- March 31, 2026
- March 31, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025
- March 2, 2026
Questions about BLTE
What does Belite Bio, Inc do?
Belite Bio, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BLTE.
Is Belite Bio, Inc profitable?
No. In fiscal 2025 it reported a net loss of $77.6M.
When did Belite Bio, Inc last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the insider trade from September 9, 2026.
Similar companies
Follow BLTE
Get an email when Belite Bio, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow BLTE: get an email when it filesWhere the numbers come from
Financial figures are the values Belite Bio, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.